The 600,000-Person Study That Just Changed Everything We Know About GLP-1s and Addiction
A VA database study of 600K+ patients found GLP-1 users had dramatically lower rates of substance use disorders across every major addictive substance — and the Swedish data backing it up may be even more impressive.
The Study That Stunned Addiction Medicine
In March 2026, epidemiologist Dr. Ziyad Al-Aly and his team at Washington University School of Medicine published what may be the most consequential GLP-1 study since the original diabetes trials. Analyzing medical records of more than 600,000 veterans in the VA healthcare system over three years, they found that patients prescribed GLP-1 medications for Type 2 diabetes experienced significantly lower rates of substance use disorders across every major addictive substance studied.
This wasn't a small signal. And it wasn't limited to one substance.
What the Numbers Actually Show
Among patients with no prior history of substance use disorder, GLP-1 users had measurably lower risk of developing one:
| Substance | Risk Reduction | New Diagnoses Prevented (per 1,000 users over 3 years) |
|---|---|---|
| Alcohol use disorder | 18% lower | ~6–7 fewer |
| Opioid use disorder | 25% lower | ~6–7 fewer |
| Nicotine dependence | ~20% lower | ~6–7 fewer |
| Cocaine use disorder | 20–26% lower | ~3–4 fewer |
| Cannabis use disorder | 14% lower | ~3–4 fewer |
But here's where it gets more striking. Among patients who already had a substance use disorder, GLP-1 use was associated with reductions in drug-related deaths, overdose events, drug-related hospitalizations, and suicide attempts. The Conversation
The Swedish Study That Independently Confirmed It
A separate Swedish nationwide study of 227,000 patients with alcohol use disorder found that GLP-1 users had a 36% lower risk of alcohol-related hospitalizations. For context, naltrexone — the best FDA-approved medication for alcohol use disorder — achieved only a 14% reduction in the same study. GLP-1s outperformed the gold standard by more than double. NBC News
How It Works: The Dopamine Connection
GLP-1 receptors aren't just in the gut and pancreas — they're also distributed throughout the brain's mesolimbic dopamine system, the same circuitry that drives reward-seeking behavior across all addictions. When GLP-1 drugs activate these receptors, they appear to modulate dopamine signaling in ways that reduce the "wanting" associated with addictive substances without completely eliminating normal pleasure responses.
Dr. Carolina Haass-Koffler, an addiction researcher at Brown University, describes the mechanism as "dialing down the volume" on cravings rather than muting them entirely. Separate NIH-funded research published in Nature in May 2026 found that oral small-molecule GLP-1 drugs like orforglipron penetrate even deeper into the brain's reward circuitry, reaching the central amygdala — a region associated with desire that scientists didn't previously think these drugs could directly reach. NIH 2026
What This Means for Patients — and What It Doesn't
No GLP-1 medication is FDA-approved for addiction treatment. These are observational findings from large datasets — not randomized controlled trials. Dedicated Phase 3 trials for alcohol use disorder are underway, with results expected in 2027–2028. But the consistency of the signal across substances, populations, and independent studies is what has addiction medicine researchers paying very close attention.
If you're currently on a GLP-1 and have noticed reduced cravings for alcohol, nicotine, or other substances, you're not imagining it. The mechanism appears to be real. But if you're considering starting a GLP-1 specifically to treat an addiction, talk to a healthcare provider first — this is still off-label territory, and addiction treatment requires comprehensive support beyond any single medication.
Some patients report anhedonia (reduced ability to feel pleasure) on GLP-1 medications. While reduced cravings can be beneficial, a flattened emotional response may indicate the medication is affecting your brain's reward system in ways that warrant discussion with your doctor.
Sources
- Al-Aly Z, et al. "GLP-1 receptor agonists and substance use disorders." The BMJ, March 2026. bmj.com
- NPR. "GLP-1 drugs like Ozempic can curb addiction risk, study finds." March 5, 2026. npr.org
- Swedish nationwide study of 227,000 patients. Reported via NBC News, March 2026. nbcnews.com
- Godschall EN, et al. "A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs in Mice." Nature, 2026. nih.gov
- Brown University School of Public Health. "A turning point in addiction psychiatry?" July 2025. sph.brown.edu
- U.S. News & World Report. "Can GLP-1s Help With Addiction?" March 2026. usnews.com